GLP-3 Triple Agonist 20mg — Research Compound
GLP-3 is a next-generation synthetic peptide that simultaneously engages three distinct metabolic receptors — glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This triple mechanism places it at the cutting edge of metabolic peptide research and represents a significant evolution beyond dual-agonist compounds.
 
About GLP-3
The addition of glucagon receptor agonism to the dual GIP/GLP-1 framework introduces a third metabolic pathway — one associated with energy expenditure, hepatic glucose output regulation, and lipid metabolism. Researchers studying next-generation approaches to metabolic biology have identified triple agonism as a particularly compelling area of investigation.
 
Current research has explored triple GIP/GLP-1/glucagon agonism in the following contexts:
Energy expenditure and basal metabolic rate signaling
Hepatic glucose production modulation
Lipid metabolism and fatty acid oxidation
Appetite and satiety pathway interaction
Comparative mechanisms versus dual and single agonist peptides
 
Why Researchers Are Watching GLP-3
Search interest in triple agonist compounds has grown over 500% year over year heading into 2026, reflecting the scientific community's growing focus on what comes after the current generation of GLP-1 based research compounds. GLP-3 represents the frontier of this research category.
 
Product Specifications
Quantity: 20mg
Form: Lyophilized powder
Purity: ≥98% (HPLC verified)
Storage: Keep refrigerated at 2–8°C, protect from light
 
For Research Use Only. Not intended for human or veterinary use. This product is not a drug, food, or cosmetic and should not be misbranded, misused, or mislabeled as such.